Fifty-three percent of psychiatric outpatients said they disliked large tablets. A third disliked red ones. And none of it—not shape, not size, not color—reached statistical significance for whether they actually took the drug.
Hold that finding. We'll come back to it, because it's the cleanest illustration of a mistake that runs through everything we do with non-drug treatments for depression.
Here's the slogan that mistake hides behind. A pharmacist, writing online, puts it perfectly: "If exercise came in a pill, it'd be the number one prescribed antidepressant in the world." Free, accessible, virtually no side effects.
And a psychiatry resident in Ottawa, Dr. Nicholas Fabiano, took it further, titling an editorial in the British Journal of Sports Medicine: "Could not prescribing exercise for depression be psychiatric malpractice?"
His logic is tight. "If we have a treatment that has the same effects as medications or psychotherapy, then we need to offer it to patients," he says. Not offering the full array of options, he argues, is a form of malpractice.
The efficacy case is genuinely strong. Fabiano cites hundreds of randomized trials; a BMJ meta-analysis reportedly of over 200 trials concluded exercise should be a first-line treatment for depression. Effect sizes for movement reportedly run from 0.42 to 1.26, per a clinical supervisor's essay—matching or beating drugs and therapy.
So the evidence is settled. Which is exactly why the slogan is a trap.
Because "if exercise were a pill" treats efficacy as the missing ingredient. It isn't. Fabiano says it himself, in the same interview: "The evidence is clear—implementation is not."
The evidence is clear—implementation is not. ‘If exercise were a pill’ treats efficacy as the missing ingredient. It isn't.
The slogan assumes a patient who will do the thing. But look at who we're prescribing to. Depression's defining features—Fabiano lists them—are "lack of motivation, lack of energy, and lack of concentration." We are handing a motivation-dependent intervention to people whose core symptom is the absence of motivation.
Prescribing exercise like a pill—a dose to be swallowed, self-administered—guarantees failure in precisely the population it targets. A pill you can take while depressed. A four-day-a-week jogging program is not a pill.
This is where the argument turns. The lever that actually moves outcomes is not the exercise. It's the delivery design around it.
Consider the single most important word in Fabiano's clinical summary: supervised. "We know, based on the literature, that supervised exercise leads to greater adherence and also greater antidepressant effects."
Read that twice. Supervision doesn't just help people show up. It produces a larger antidepressant effect. The delivery form is not neutral packaging around an active drug—it is part of the active dose.
And Fabiano is precise about when this matters most: "in the early phases of depression where innate features like lack of motivation, lack of energy, and lack of concentration are defining features." Supervision substitutes for the motivation the patient doesn't have. It borrows structure from outside the depressed nervous system until the system can generate its own.
This reframes what a "prescription" for exercise even is. You cannot write "brisk walking, 30 minutes, four times weekly" and call it care. That's a dose with no delivery system. The delivery system is a person, a time, a place, a group—someone who notices when you don't come.
Fabiano is honest that psychiatrists can't do this themselves: they can't supervise exercise programs while running full clinics. The supervision has to be built, structurally, through partnerships with fitness professionals. That's system redesign, not a prescription.
Now go back to those tablets—the ones patients disliked but took anyway.
The study followed 232 outpatients. Overall adherence was 74.1 percent. Patients reportedly disliked large tablets (53.4 percent) and red pills (33.6 percent). Yet no attribute reached statistical significance for adherence.
The naive reading: aesthetics don't matter. The sharper reading: the aesthetics of a swallowed pill are a weak lever, because swallowing is nearly frictionless to begin with. The delivery form is already so low-effort that tweaking its shape barely registers.
But look where adherence collapsed. In psychosis, only 30.8 percent were adherent—against 74 percent overall—though this came from a very small subgroup with a wide confidence interval (12.7–57.6 percent), so the figure should be read cautiously. The variable that mattered wasn't the pill's color. It was the state of the person receiving it, and the support structure around them.
That's the lesson for exercise. If a low-friction intervention like swallowing a tablet still fails hardest in the sickest patients, imagine what happens to a high-friction intervention—a workout—handed to the same population with no scaffolding. The delivery gap doesn't shrink. It explodes.
There's a communication analogue too. Pharmacist counselling is being redesigned away from what one framework, CONNECT-6, calls "directive monologue" toward "collaborative dialogue"—structured two-way exchange, empathy, shared goal-setting, rather than the one-way transfer of instructions.
The parallel to exercise is exact. Handing someone an exercise prescription and walking away is monologue. It assumes the message received equals the behavior performed. Dialogue—checking, adjusting, supervising, collaborating on the goal—is what actually moves adherence, in the pharmacy and on the trail alike.
Then there's the most elegant lever of all: removing the willpower tax entirely.
Walkable neighborhoods—high street connectivity, mixed land use, real pedestrian infrastructure—are associated with 68 to 89 additional minutes of physical activity per week. Not through motivation. Through geometry.
The mechanism is the whole point. Walkable design, as the researchers put it, "integrates healthy behaviors into daily routines" rather than "requiring sustained motivation." The activity happens because the errand happens. You walk to the shop because the shop is walkable to.
For a population defined by depleted motivation, this is the ideal delivery form. It asks for nothing. It lowers psychological distress by rearranging the environment so the healthy behavior becomes the path of least resistance—the default, not the effort.
Compare the two ends of the spectrum. A self-directed exercise plan demands maximum motivation from the person with the least. A walkable street demands none. Same "active ingredient"—physical activity. Radically different delivery. Radically different odds of adoption.
Which brings us back to why standard care neglects all of this.
Supervision, dialogue frameworks, walkable streets—none of them fit on a prescription pad. They require staffing, referral networks, urban planning, budgets, coordination across professions. They are, in a word, infrastructure.
A prescription is a single act by a single clinician in a single visit. Redesigning delivery is a system problem, and systems are harder to change than sentences. So we default to the sentence: "Try to get some exercise." The malpractice, if there is one, isn't failing to say it. It's saying it and calling that treatment.
Fabiano gestures at one more dimension worth naming precisely: the group. He notes that supervised, communal exercise supplies social connection to people who isolate when depressed—and that the literature on connection itself is large. (That element, the social dose inside the exercise dose, is quantified more directly in this issue's Connection Cure piece.)
But even setting connection aside, the core argument stands on its own. The exercise-versus-drugs debate has been won on efficacy and lost on delivery.
We spend enormous care on dosing curves for pills—time-course, dose-effect, titration. We should spend the same seriousness on the delivery curves of everything else: who supervises, when in the illness, in what group, along what street.
Treating those details as soft, secondary, "lifestyle" concerns is the actual clinical failure. Because a first-line treatment nobody can adhere to is not a first-line treatment.
It's a slogan.